New antibiotic combo tested in kids to fight superbug infections
NCT ID NCT06801223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing an antibiotic called Sulbactam-Durlobactam in hospitalized children from birth to under 18 years old who have or may have an Acinetobacter infection. The goal is to find the right dose and check that it is safe. About 48 children will receive the drug through an IV at different schedules. This is an early-stage trial, so it focuses on how the drug moves through the body and any side effects, not yet on curing the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sulbactam-Durlobactam (an antibiotic combination)
- What this could lead to
- If successful, this could provide a safe and effective antibiotic dosing regimen for children with hard-to-treat Acinetobacter infections.
- What could go wrong
- This is a very early phase 1b study with only 48 children, so it is primarily checking safety and drug levels, not yet proving the drug works. Side effects are possible, and the results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX INFECTION (ABC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECU Brody School of Medicine
RECRUITINGGreenville, North Carolina, 27834, United States
-
Rady Children's Hospital
RECRUITINGSan Diego, California, 92123, United States
-
UCLA Medical Center
RECRUITINGLos Angeles, California, 90095, United States
-
University of Texas Medical Branch at Galveston
RECRUITINGGalveston, Texas, 77555-5302, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.